Published in J Natl Compr Canc Netw on August 01, 2011
Biosimilars: part 1: proposed regulatory criteria for FDA approval. P T (2013) 1.19
Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden. Biol Ther (2013) 1.03
Biosimilars: part 2: potential concerns and challenges for p&t committees. P T (2013) 0.99
Evaluation of Biosimilars for Formulary Inclusion: Factors for Consideration by P&T Committees. P T (2015) 0.78
Is the decision on the use of biosimilar growth hormone based on high quality scientific evidence? - a systematic review. Eur J Clin Pharmacol (2014) 0.77
Biosimilars Are Here: A Hospital Pharmacist's Guide to Educating Health Care Professionals on Biosimilars. Hosp Pharm (2015) 0.75
Biosimilars: new promise for reducing healthcare costs. J Biomed Res (2014) 0.75
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26
Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2011) 7.24
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer (2006) 5.03
Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med (2008) 4.71
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2012) 4.42
Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood (2008) 4.06
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol (2007) 4.06
American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol (2013) 4.03
Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer (2006) 3.86
Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer (2007) 3.27
Retracted Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA (2008) 3.26
Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer (2004) 3.15
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol (2011) 2.76
NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw (2011) 2.73
Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer (2011) 2.67
Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care (2005) 2.37
Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med (2005) 2.25
Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer (2005) 2.20
Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol (2006) 2.17
Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol (2005) 2.13
The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion (2007) 2.12
Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol (2006) 2.03
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol (2012) 2.02
Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol (2007) 1.92
Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med (2008) 1.85
American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges. J Clin Oncol (2008) 1.75
Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res (2010) 1.66
Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw (2008) 1.65
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. Ann Surg Oncol (2012) 1.56
A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer (2007) 1.54
Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet Med (2012) 1.39
Variation in the cost of medications for the treatment of colorectal cancer. Am J Manag Care (2008) 1.39
Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol (2005) 1.38
Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. J Clin Oncol (2008) 1.27
Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. Ann Intern Med (2014) 1.27
Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat (2006) 1.25
Undertreatment of cancer patients with chemotherapy is a global concern. J Oncol Pract (2008) 1.23
Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 1.23
Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol (2009) 1.21
Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer (2004) 1.16
Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health (2008) 1.14
Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw (2003) 1.14
Myeloid growth factors. J Natl Compr Canc Netw (2013) 1.13
American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. J Clin Oncol (2012) 1.12
Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. J Clin Oncol (2011) 1.12
Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer (2007) 1.11
ASCO Clinical Practice Guidelines: Past, Present and Future. J Oncol Pract (2008) 1.10
Costs associated with febrile neutropenia in the US. Pharmacoeconomics (2012) 1.06
Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. Gynecol Oncol (2012) 1.04
Myeloid growth factors. J Natl Compr Canc Netw (2011) 1.03
Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study. Cancer Med (2014) 1.03
Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. Genet Med (2012) 1.03
Antiemetics: american society of clinical oncology clinical practice guideline update. J Oncol Pract (2011) 1.02
Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. Cancer (2009) 1.02
Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects. J Natl Cancer Inst (2013) 0.98
The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. J Natl Compr Canc Netw (2008) 0.96
Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice. Breast Cancer Res Treat (2012) 0.96
Breast cancer screening with mammography. Curr Oncol Rep (2011) 0.95
Myeloid growth factors. J Natl Compr Canc Netw (2009) 0.94
Venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma (2006) 0.93
Hemopoiesis and aging. Cancer Treat Res (2005) 0.93
Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. J Oncol Pharm Pract (2013) 0.93
Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. Crit Rev Oncol Hematol (2009) 0.92
The colony-stimulating factors: use to prevent and treat neutropenia and its complications. Expert Opin Biol Ther (2004) 0.90
Comparison of demographic characteristics, surgical resection patterns, and survival outcomes for veterans and nonveterans with non-small cell lung cancer in the Pacific Northwest. J Thorac Oncol (2011) 0.90
Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health (2008) 0.89
Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. J Natl Cancer Inst (2011) 0.89
Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. Gynecol Oncol (2012) 0.88
Time is money for both the healthy and the sick. Med Care (2005) 0.88
Sentinel node biopsy for head and neck melanoma: a systematic review. Otolaryngol Head Neck Surg (2011) 0.87
A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs. Value Health (2012) 0.87
Will biosimilars gain momentum? J Natl Compr Canc Netw (2013) 0.87
Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy. Med Care (2011) 0.87
Ductal carcinoma in situ: a review of recent advances. Curr Opin Obstet Gynecol (2007) 0.87
Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients. Breast Cancer Res Treat (2011) 0.87
Screening mammography at 40-49 years: regret or no regret? Lancet (2006) 0.86
Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. Cancer Invest (2009) 0.86
Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries. Am J Med (2004) 0.85
Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials. Cancer Treat Rev (2006) 0.85
Commentary: should cost and comparative value of treatments be considered in clinical practice guidelines? J Oncol Pract (2011) 0.85
Availability of experimental therapy outside oncology randomized clinical trials in the United States. J Clin Oncol (2010) 0.85
Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery. J Hematol Oncol (2010) 0.84
Short-term costs associated with primary prophylactic G-CSF use during chemotherapy. Am J Manag Care (2013) 0.84
ASCO Clinical Practice Guidelines and Beyond. J Oncol Pract (2007) 0.84
Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses. J Med Econ (2013) 0.83
Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer. Breast Cancer Res Treat (2010) 0.82
The impact of anaemia and its treatment on employee disability and medical costs. Pharmacoeconomics (2005) 0.82
Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model. Cancer (2012) 0.81
Commentary: chemotherapy dosing in obese patients with cancer-the need for evidence-based clinical practice guidelines. J Oncol Pract (2011) 0.81
Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer. Crit Rev Oncol Hematol (2013) 0.81
Predictors of chemotherapy-induced neutropenia and its complications: results from a prospective nationwide registry. J Support Oncol (2005) 0.80
Myeloid growth factors clinical practice guidelines in oncology. J Natl Compr Canc Netw (2005) 0.80
Pharmacoeconomics of the myeloid growth factors: a critical and systematic review. Pharmacoeconomics (2012) 0.79
Burden of pancreatic cancer and disease progression: economic analysis in the US. Oncology (2006) 0.79
Benefits of GM-CSF Versus Placebo or G-CSF in Reducing Chemotherapy-Induced Complications: A Systematic Review of the Literature. Support Cancer Ther (2004) 0.79
Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer. Pharmacoeconomics (2012) 0.78
Preventing VTE in Outpatients With Cancer. Chest (2012) 0.78